2020 France Cancer Diagnostics Market: Supplier Shares and Strategies by Test, Volume and Sales Segment Forecasts, Emerging Tumor Markers, Technologies and Instrumentation

March 2020 | 585 pages | ID: 207932C572A7EN
Venture Planning Group

Abstracts

VPGMarket's new report is a study of the major business opportunities emerging in the French cancer diagnostics market during the next five years. The report examines trends in the French cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

France Market Overview

• Five-year test volume and sales projections.
• Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.
• Estimated universe of laboratories performing cancer diagnostic testing.
• Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Z

Over 200 Current and Emerging Cancer Diagnostic Test

• Biochemical Markers
• Oncogenes
• Growth Factors
• Hormones
• Colony Stimulating Factors
• Lymphokines
• Immunohistochemical Stains, and others.

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

• Sales and market shares of major cancer diagnostic product suppliers by individual test.
• Five-year test volume and sales forecasts for major tumor markers by market segment, including:
  • Hospitals
  • Commercial/Private Laboratories

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

• Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
• Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 585 pages and 95 tables

Contents

I. INTRODUCTION

II. MARKET OVERVIEW

A. Market Overview
B. Worldwide Market Structure
C. Worldwide Market Size and Growth

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

VII. MARKET AND TECHNOLOGY OVERVIEW

A. Major Current and Emerging Cancer Diagnostic Tests
  1. Biochemical Tumor Markers
  2. Oncogenes
  3. Polypeptide Growth Factors
  4. Ectopic Hormones
  5. Colony Stimulating Factors
  6. Lymphokines
  7. Immunohistochemical Stains
  8. Emerging Tumor Markers
B. Instrumentation Review and Market Needs
C. Current and Emerging Technologies
D. Personal Testing

VIII. COUNTRY ANALYSIS

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Dynamics, Trends, Size and Growth
  Volume Forecasts by Test and Market Segment
  Sales Forecasts by Test and Market Segment
  Major Supplier Sales and Market Shares

IX. COMPETITIVE PROFILES

Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
CellSearch
Cepheid
Clinical Genomics
Decode Genetics
DiaSorin
Diazyme
Eiken Chemical
Elitech Group
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Guided Therapeutics
Hologic
Janssen Diagnostics
Kyowa Medex
Leica Biosystems
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
PerkinElmer
Polymedco
Qiagen
Quest Diagnostics
Roche
Scienion
Sequenom
Siemens Healthineers
Takara Bio
Theradiag
Thermo Fisher
Tosoh
Vermillion
Wako Pure Chemicals

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS